EndoPredict has a depth of clinical evidence in patients with ER positive/HER2 negative early-stage breast cancer, established in over 3,500 patients, across 5 validation trials, and with up to 15 years of clinical data in some women.1-7
EndoPredict is validated across node positive and node negative patients, as well as both premenopausal and postmenopausal women – the only second generation breast cancer recurrence gene expression test to do so.
This second generation test is recommended by many international and national guidelines to help clinicians and their patients make confident chemotherapy treatment decisions together, and provide information about need for long-term endocrine therapy.
EndoPredict is independently validated for robust prognostic results.1-4
EndoPredict is the only test providing breast cancer recurrence risk up to 15 years.2
Learn more about how EndoPredict provides a 15-year recurrence risk
EndoPredict has the first prospective validation of prognostic risk classification for a second generation gene expression test in a randomized trial of node positive, clinically high-risk, chemotherapy-treated patients.9
EndoPredict impacts therapeutic decision-making, reflected in the published decision impact studies in this table, which enrolled over 1,000 patients across five different countries.9-14
Learn more about EndoPredict publications below.
A prospective French registry (SiMoSein) with more than 4,700 patients presented at ESMO 2021 emphasizes the clinical need for gene expression testing to avoid over and under treatment.15
This data illustrates that gene expression assays such as EndoPredict are the cornerstone for assessment of prognosis in patients with early ER positive, HER2 negative breast cancer. With 4,766 patients from 14 laboratories, the French national registry SiMoSein is the largest registry worldwide for patients tested with EndoPredict in a real-world setting.
Other prospective data are also expected soon for EndoPredict in the ongoing RESCUE study. Find out more on our clinical trials page.
You can find all of these studies on our publications page, where you can find a full list of published materials to support EndoPredict. Summaries of the key EndoPredict studies can also be found on our clinical summaries page.